A PYMNTS Company

UK: GlaxoSmithKline agrees to buy Tesaro for $4.5bn

By  |  December 3, 2018

Tesaro shares surged 58% Monday after GlaxoSmithKlineagreed to buy the cancer treatment company for $75 per share, or about $5.1 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The deal represents a more than 60% premium over Tesaro’s closing price on Friday of $46.38 per share. GlaxoSmithKline’s stock was 8.2% lower Monday.

    “The acquisition of Tesaro will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities,” GlaxoSmithKline CEO Emma Walmsley said in a statement.

    The acquisition hands Glaxo Tesaro’s ovarian cancer drug Zejula, which went on sale in the US and Europe last year. Zejula is one of a new class of drugs known as PARP inhibitors, which have increased survival rates for women with recurrent ovarian cancer. PARP inhibitors are also showing promise in other forms of cancer, such as lung, breast and prostate.

    Full Content: Wall Street Journal
    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.